Amundi
IONS icon

Amundi’s Ionis Pharmaceuticals IONS Stock Holding History

Amundi’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.8M Sell
23,958
-436,989
-95% -$34.5M ﹤0.01% 1127
2025
Q4 		$36.5M Buy
460,947
+359,416
+354% +$27.1M 0.01% 706
2025
Q3 		$7.01M Buy
+101,531
New +$4.96M ﹤0.01% 911
2025
Q2 		– Sell
-3,873
Closed -$110K – 1911
2025
Q1 		$110K Sell
3,873
-7,501
-66% -$246K ﹤0.01% 1737
2024
Q4 		$388K Sell
11,374
-116,925
-91% -$4.37M ﹤0.01% 1618
2024
Q3 		$4.85M Sell
128,299
-1,176
-0.9% -$54.7K ﹤0.01% 986
2024
Q2 		$5.9M Sell
129,475
-11,301
-8% -$464K ﹤0.01% 934
2024
Q1 		$5.75M Sell
140,776
-131,874
-48% -$6.29M ﹤0.01% 943
2023
Q4 		$14.4M Buy
272,650
+146,986
+117% +$7.04M 0.01% 768
2023
Q3 		$6.03M Buy
125,664
+4,818
+4% +$199K ﹤0.01% 939
2023
Q2 		$4.96M Buy
120,846
+115,478
+2,151% +$4.44M ﹤0.01% 990
2023
Q1 		$196K Buy
5,368
+1,775
+49% +$66.7K ﹤0.01% 1572
2022
Q4 		$136K Buy
+3,593
New +$151K ﹤0.01% 1567

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi's IONS Position: Q1 2026 in Review

Amundi reduced its Ionis Pharmaceuticals (IONS) stake by 95% in Q1 2026, selling an estimated $34.5M and leaving 23,958 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1127.

Amundi first reported a position in IONS in Q4 2022 and has held it in 13 quarters since. The position peaked at $36.5M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Amundi held 23,958 shares of Ionis Pharmaceuticals worth $1.8M as of Q1 2026.
  • Amundi sold 436,989 Ionis Pharmaceuticals shares in Q1 2026, an estimated $34.5M.
  • Ionis Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1127 holding.
  • Amundi first reported a position in Ionis Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • Amundi's Ionis Pharmaceuticals position peaked at $36.5M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.